When you build products, you’re making bets — not certainties. The best product teams don’t pretend to know the answer or wait until all data clears the fog. Instead, they “think in bets.” That means approaching each decision like a poker player, not a chess grandmaster.

Most people treat product roadmaps as if they’re a set of sure things: follow steps A, B, and C, and you’ll win. But real product work faces incomplete data and random outcomes. As Annie Duke puts it in her book, Thinking in Bets:

“What makes a decision great is not that it has a great outcome. A great decision is the result of a good process...”

So, what’s the process?

First, treat every new idea — a feature, a redesign, a pivot — as a “hypothesis.” Will this change actually improve something users care about? Write it down in simple terms, like: “If we build an onboarding guide, new users will activate 20% faster.”

Now, here’s where the betting mindset helps. It asks:

• How confident are we?
• What info could prove us wrong?
• What’s the easiest, cheapest way to test this in the real world?

Quick bets matter because the future is fuzzy. If you gamble 12 months on a huge launch without real-world data, you might be in for a nasty surprise. Instead, top teams borrow from poker pros and run smaller experiments — MVPs, A/B tests, surveys with context. They measure, learn, and shift their bets if the early evidence says “nope.”

Spotify is a good example. Their “bets board” is a public way to show which pitches are actual priorities, what’s being tested, and which ones move on after the first round. Nothing sits still. If the initial result flops, the team adapts or walks away.

This approach also helps avoid “resulting” — blaming or praising people based mainly on whether the final result was good or bad. Duke explains (via Evan's Notes):

“Just because you lose doesn’t mean you made a bad decision. And just because you win doesn’t mean you made a good one.”

The product is a game that combines luck and skill. Short, smart experiments let you learn fast, place more bets, and react before it’s too late.

So next time you face 20 options, resist the urge to play it safe and delay until you “know for sure.” Instead, pick a handful, write out hypotheses, and ask: “What’s our bet? How will we know if it’s working?” Ship small. Learn fast. Then double down where the evidence is strong.

That’s real product strategy: it’s not about avoiding risk, but managing it—one bet at a time.

When it comes to getting your product into the hands of customers, many new product managers start with the channel. They ask, “Should we sell through partners, go viral, or build a sales team?”

Ben Horowitz puts it simply:

“A properly designed sales channel is a function of the product that you have built and the target … that you wish to pursue.”

In other words, the product and the target market come first. The channel comes later.

Let’s break that down.

Think of the channel as the path your product takes to reach the customer. This path depends on two things:

1. What your product does
2. Who it is for

If you skip straight to picking a channel without thinking about those two things, you risk picking the wrong path.

Here’s a simple example

You are a PM at a startup called MedTrack. You’ve built a platform that helps mid-size hospitals track the status of equipment like MRI machines, ventilators, and infusion pumps. The product reduces downtime and avoids missed appointments.

Your target market is hospital administrators and biomedical engineering teams. They care about reliability, compliance, and cost savings. They work in regulated environments and require robust data security measures.

Given the product and target, what channel makes sense? Probably not a self-serve website with a credit card sign-up. Your buyers need trust and proof. They may want demos and integration planning.

A better path would be:

• Inside sales teams who can book demos with administrators
• Industry conferences where decision-makers attend
• Partnerships with hospital IT system vendors who can refer your product

Now imagine if you had skipped the product and target thinking. You might have copied a popular startup and gone for a viral, freemium model. That could bring in lots of small clinics or even individual doctors, but your platform is not designed for them. You would spend time chasing the wrong audience.

The lesson is simple.

Start with your product’s strengths and the needs of your target customers. Let those define the best way to reach them. The formula is:

Product + Target = Channel

Not the other way around.

Here’s another quote worth keeping in mind:

“When I ask new entrepreneurs what their distribution model will be… ‘distribute our product like Dropbox did.’ … demonstrates a deep misunderstanding of how sales channels should be designed.”

For new product managers, the takeaway is this: Do not pick a channel because it worked for someone else. Pick it because it fits what you are selling and who you are selling to. That is how you set up your product for growth.

The press around AI putting pressure on well-established SaaS companies is gaining some momentum.

Note: We are not discussing specific stocks and valuations. Our focus is on the impact of AI on software companies.

Analyst Ratings Published 08/11/2025…

"Melius Research downgraded Adobe… warns of ongoing multiple compression for software-as-a-service companies… ‘AI is eating software’ …”

AI isn’t a shiny add-on anymore. It’s like a sneaky wave that’s pushing SaaS valuations lower. Investors see that and say: This might be more than a passing trend.

“Redburn-Atlantic downgraded shares to Sell, warning that generative AI tools are eroding the company’s competitive advantage …”

When analysts note genAI is eating away at your moat, that’s a red flag. For product folks, that means no more resting on past glory. You have to rethink the value your product brings.

On a related note:

“Atlassian laid off about 150 employees… AI will replace many support and operations roles to cut costs and boost efficiency.”

Jobs are vanishing because AI can now handle repetitive tasks.

---

For us on the product side, that points to two things: rising expectations for automation and shrinking tolerance for any friction.

These moves aren’t just headlines. They reflect a shift in how markets see SaaS. Using Adobe as an example, there are several software companies facing similar scrutiny.

When AI starts chiming that its tools can do your job faster or cheaper, investors get jittery. That changes how product managers should think: it’s no longer enough to polish features. AI-first competitors or internal automation can upend your roadmap in weeks.

The message from Wall Street? If the AI around your space is improving fast, your users could be just one model away from switching. And it’s not just about competition—it’s about cost, integration, and perceived value. If your AI isn’t sticky, it’s replaceable.

For product leaders reading this, here’s what’s buzzing in the market:

• Valuation risk is real, even for heavy hitters. If you don’t keep your competitive edge, investors will punish multiples fast.
• Expect AI to be a force multiplier or a replacement. Your value-props need to lean into what only you can do—be it deep domain context or specific workflows.
• Speed matters. Markets are reacting now, not in some distant “AI future.” You’ve got to move on to experiments, integrations, or whatever keeps your product relevant.

This isn’t about doom-scrolling or hype. It’s about reading the room. Adobe’s drop says investors are cautious. Atlassian’s restructuring signals that internal teams are already adapting to AI. By now, you should all be seeing these shifting trends in your product areas and business.

As product managers, those aren’t distant storms—they’re the new normal.

From WSJ piece on Warby Parker:

Many things have gotten pricier in the past 15 years. Not Warby Parker's most affordable glasses, which have cost $95 since the brand’s inception in 2010.

Warby Parker grew 14% last year. It did this while keeping its hero $95 price point. This shows that a focused value proposition can thrive even with inflation. The company used a few key strategies. It controlled its supply chain. It created a tiered pricing model. It constantly refreshed its product line.

Why this matters for product leaders:

Warby Parker proves that a single, resonant value proposition can survive. It even thrives through tariffs and inflation. The $95 anchor creates a clear mental model for shoppers. It forces every internal decision to prioritize affordability.

How Warby Parker Enables Growth

Vertical integration is a cost shock absorber. The company owns two optical labs in the U.S. It runs its own stores and e-commerce. This allows Warby to bypass some tariff impacts. It can move production out of China. It can also iterate on SKUs faster than rivals.

It uses a price ladder instead of across-the-board hikes. About 60% of frames still start at $95. But progressive lenses, blue-light filters, and new designs move customers into higher price points. This has lifted revenue per customer every year since the 2021 IPO.

The "forever price" creates a psychological moat. Holding the $95 price for 15 years builds trust. Even minor increases on premium SKUs feel reasonable. Competitors raised their entry prices multiple times.

The company is expanding its demographic. It targets aging consumers who need pricier progressive lenses. This offsets softness among younger, more price-sensitive buyers. It broadens the total addressable market without changing the brand ethos.

Takeaways for Product and Design

Invest in a flagship offering that never changes. Innovate around the edges. Each new frame style or lens upgrade drives upsell. The flagship price anchors customer perception. This balances consistency and novelty to stay relevant.

What PMs Can Steal Today

Protect your base plan or entry SKU. Make your finance team justify any changes to it.

Build flexibility into your production. Own or partner on production to protect pricing.

Use anchoring to make premiums feel like upgrades. They should not feel like price gouging.

Segment by life stage and functional need. Progressive lenses are Warby Parker's pro tier.

Warby Parker's playbook shows that growth is not about volume at all costs. It is about defending the core promise. Then widen the margins around it. Do this with customer-aligned innovation.

At some point, Warby Parker's base price offering will go up. Nevertheless, with that 15-year track record, this is a successful case study of anchoring value prop around your core offering.

Yesterday, we explored how AI transforms medical understanding, informing patients. Today, let's examine where AI actually delivers results in clinical practice. New research from the Journal of Clinical Medicine maps the gap between hype and reality. Resonates well with my personal experience.

"The central challenge is evident: as AI tools become more sophisticated, our capacity to integrate them ethically, equitably, and effectively into clinical practice must evolve in tandem. This editorial explores the remarkable progress in AI-driven medicine, identifies critical gaps that hinder its full potential, and highlights the collaborative efforts necessary to build a patient-centered future."

Where AI Works Today

AI succeeds in four key areas right now (confining to this research, there are several more that I am aware of):

Imaging leads the pack. The FDA has approved over 600 AI medical devices, with 75% focused on radiology. IDx-DR detects diabetic retinopathy with 87% sensitivity. Aidoc flags brain hemorrhages 96% faster than standard workflows. These aren't experiments. They're deployed in hundreds of hospitals.

Drug discovery shows measurable wins. Atomwise identified new Ebola treatments in days, not years. BenevolentAI found baricitinib as a COVID treatment in four days. Insilico Medicine took a novel drug target to clinical trials in 18 months. Traditional timelines? Three to six years.

Clinical decision support reduces errors. Epic's sepsis prediction model alerts doctors six hours earlier than standard protocols. Johns Hopkins reduced readmissions by 26% using machine learning on discharge planning. Mount Sinai's deep learning system predicts acute kidney injury 48 hours in advance.

Administrative tasks get faster. Nuance's Dragon Medical reduces documentation time by 45%. Carbon Health's AI scheduling fills 30% more appointment slots. Prior authorization that took days now takes hours.

The Implementation Gap

But most AI projects fail. Here's why.

Data quality kills promising tools. Hospital systems average seven different EMR formats. Lab results use different units. Missing data reaches 30% in some fields. You can't train models on chaos.

Integration breaks workflows. Adding new software to 20-year-old systems isn't simple. Doctors already click 4,000 times per shift. New tools that add steps get abandoned. Memorial Sloan Kettering spent $62 million on IBM Watson before pulling the plug.

Regulations slow everything down. FDA approval takes 12 months minimum. HIPAA compliance adds complexity. Europe's MDR requirements doubled documentation needs. Each country has different rules.

Trust remains fragile. Only 38% of physicians feel comfortable with AI recommendations. Patients worry about privacy. Blackbox algorithms face liability questions nobody can answer yet.

What Actually Moves the Needle

Successful deployments share patterns.

Start with narrow problems. Olive AI began with insurance verification only. They process 5 million claims monthly. Broader platforms struggle. Focused tools ship.

Augment, don't automate. Pathology AI highlights areas of concern, but pathologists make diagnoses. Radiology AI prioritizes urgent cases, but radiologists read them. Tools that support beat tools that replace.

Measure patient outcomes. Accuracy means nothing if patients don't improve. Ochsner Health's hypertension AI showed 71% blood pressure control rates versus 31% standard care. That's what matters.

Build learning systems. Cleveland Clinic's models improve monthly from feedback. Static algorithms become obsolete fast.

The Next 12 Months

Multimodal models will combine lab results, imaging, and notes simultaneously.

Personalized predictions will replace population averages. Your genetic profile, lifestyle, and history will generate custom risk scores.

Real-world evidence will separate winners from losers. Deployment data from thousands of hospitals will reveal what actually works.

The winners won't be the most sophisticated algorithms. They'll be the ones that fit into Tuesday morning rounds without adding friction.